

Q-linea participates in first Italian public tender

Q-linea AB (publ) (OMX: QLINEA) today announces that the company has participated in a public tender in Italy with the ASTar® Instrument and Consumables.

“This tender is one of the first we have seen in Italy with a specific focus on rapid AST solutions directly from positive blood culture bottles and we are excited to participate with ASTar Instrument and Consumables. We know there are preparations for tenders at other sites and are very optimistic about the competitiveness of ASTar,” said Thomas Fritz, Chief Commercial Officer at Q-linea.

“It is encouraging to see tender activity picking up in one of the major diagnostic markets in Europe. To us, it is proof that the decision to build our own legal presence in Italy was correct. We do not plan to communicate our participation in every tender in the future, but since this is the first we respond to as Q-linea, we would like to share this news,” said Jonas Jarvius, CEO and President at Q-linea.

About ASTar Instruments and ASTar BC G-Kit

ASTar Instrument and ASTar BC G-Kit already deliver the broadest answer regarding the combination of the number of antibiotics and the number of double dilution steps of each antibiotic, in a single analysis for gram-negative bacteria. The test enables the analysis of gram-negative bacteria, including difficult-to-grow so-called fastidious bacteria, which satisfies the need for rapid and comprehensive results to support optimal treatment decisions.

ASTar Instrument and ASTar BC G-Kit are CE-marked but not FDA 510(k)-cleared and not available for sale in the United States.

For more information, please contact:

Jonas Jarvius, CEO, Q-linea AB

Jonas.Jarvius@qlinea.com

+46 (0) 70-323 77 60

Christer Samuelsson, CFO /IR, Q-linea AB

Christer.Samuelsson@qlinea.com

+46 (0) 70-600 15 20

About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

Attachments

Q-linea participates in first Italian public tender